APA (7th ed.) Citation

Pilotto, S., Grizzi, G., Sperduti, I., Simbolo, M., Vicentini, C., Caliò, A., . . . Corbo, V. (2018). 1417PPreliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy292.039

Chicago Style (17th ed.) Citation

Pilotto, S., et al. "1417PPreliminary Results of PRINCiPe (predictors of Resistance to Immunotherapy with Nivolumab [NIV]) Study in Advanced Pretreated Non-small Cell Lung Cancer (APNSCLC), Investigating the Role of an Immune Genomic Signature (IGS) Including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 Alterations." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy292.039.

MLA (9th ed.) Citation

Pilotto, S., et al. "1417PPreliminary Results of PRINCiPe (predictors of Resistance to Immunotherapy with Nivolumab [NIV]) Study in Advanced Pretreated Non-small Cell Lung Cancer (APNSCLC), Investigating the Role of an Immune Genomic Signature (IGS) Including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 Alterations." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy292.039.